NASDAQ:ALRNAileron Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aileron Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.07 -0.05 (-4.46 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$1.03Now: $1.07▼$1.1250-Day Range$0.69MA: $1.16▼$1.6252-Week Range$0.25Now: $1.07▼$1.99Volume772,600 shsAverage Volume546,798 shsMarket Capitalization$40.85 millionP/E RatioN/ADividend YieldN/ABeta3.72 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Aileron Therapeutics has a potential upside of 227.1% from its current price of $1.07.Amount of Analyst CoverageAileron Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAileron Therapeutics has received 190 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAileron Therapeutics has received 172 “underperform” votes. (Add your “underperform” vote.)Community SentimentAileron Therapeutics has received 52.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote “Outperform” if you believe ALRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $257,075.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 6.37% of the stock of Aileron Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALRN Previous Symbol CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone617-995-0900Debt Debt-to-Equity Ratio0.46 Current Ratio2.23 Quick Ratio2.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book1.84Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-29,370,000.00 Net MarginsN/A Return on Equity-147.06% Return on Assets-95.56%Miscellaneous Employees23 Outstanding Shares38,180,000Market Cap$40.85 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:ALRN Rates by TradingView Receive ALRN News and Ratings via Email Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions How has Aileron Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALRN shares have increased by 165.4% and is now trading at $1.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aileron Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aileron Therapeutics. When is Aileron Therapeutics' next earnings date? Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aileron Therapeutics. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics Inc (NASDAQ:ALRN) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.04. View Aileron Therapeutics' earnings history. What price target have analysts set for ALRN? 3 equities research analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 227.1% from the stock's current price. View analysts' price targets for Aileron Therapeutics. What are Wall Street analysts saying about Aileron Therapeutics stock? Here are some recent quotes from research analysts about Aileron Therapeutics stock: 1. According to Zacks Investment Research, "Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. " (6/2/2020) 2. HC Wainwright analysts commented, "Our $6 price target is based on probability-adjusted forecasts for ALRN-6924 for myelopreservation, and ALRN-6924 in combination with Ibrance in MDM2-amplified solid tumor patients." (9/11/2019) Has Aileron Therapeutics been receiving favorable news coverage? News coverage about ALRN stock has trended extremely negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Aileron Therapeutics. Are investors shorting Aileron Therapeutics? Aileron Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 955,800 shares, an increase of 57.5% from the June 15th total of 606,700 shares. Based on an average trading volume of 953,700 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.8% of the shares of the stock are sold short. View Aileron Therapeutics' Current Options Chain. Who are some of Aileron Therapeutics' key competitors? Some companies that are related to Aileron Therapeutics include Avenue Therapeutics (ATXI), Scpharmaceuticals (SCPH), Galectin Therapeutics (GALT), Cerecor (CERC), Evofem Biosciences (EVFM), Kindred Biosciences (KIN), Tyme Technologies (TYME), Cyclerion Therapeutics (CYCN), vTv Therapeutics (VTVT), Aquestive Therapeutics (AQST), Aldeyra Therapeutics (ALDX), PhaseBio Pharmaceuticals (PHAS), Mustang Bio (MBIO), Evelo Biosciences (EVLO) and Minerva Neurosciences (NERV). View all competitors. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Amarin (AMRN), Agile Therapeutics (AGRX), Lexicon Pharmaceuticals (LXRX), Opko Health (OPK), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), OpGen (OPGN), Acasti Pharma (ACST) and Advanced Micro Devices (AMD). Who are Aileron Therapeutics' key executives? Aileron Therapeutics' management team includes the following people: Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)Mr. Richard J. Wanstall, VP of Fin. & OperationsDr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52) When did Aileron Therapeutics IPO? (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What is Aileron Therapeutics' stock symbol? Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN." How do I buy shares of Aileron Therapeutics? Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aileron Therapeutics' stock price today? One share of ALRN stock can currently be purchased for approximately $1.07. How big of a company is Aileron Therapeutics? Aileron Therapeutics has a market capitalization of $40.85 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe. What is Aileron Therapeutics' official website? The official website for Aileron Therapeutics is www.aileronrx.com. How can I contact Aileron Therapeutics? Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
